Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
CC1=CC=C(C=C1NC1=NC(=CC=N1)C1=CN=CC=C1)C(=O)NC1C=C(C=C(C=1)C(F)(F)F)N1C=NC(C)=C1
inhibits proliferation
non-small cell lung cancer
Nitazoxanide: a first-in-class broad-spectrum antiviral agent
Empagliflozin - CAS# 864070-44-0 Catalog No.:M10131-10 CC1=CC=C(C=C1NC1=NC(=CC=N1)C1=CN=CC=C1)C(=O)NC1C=C(C=C(C=1)C(F)(F)F)N1C=NC(C)=C1Empagliflozin, also known as BI10773 (trade name Jardiance), is drug approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), and causes sugar in the blood to be absorbed by the kidneys and eliminated in urine. Empagliflozin is an inhibitor of the sodium glucose co transporter 2 (SGLT 2), which is
US$ 22.10
US$ 11.90
US$ 27.83